Gibson Jennifer L, Bean Sally, Chidwick Paula, Godkin Dianne, Sibbald Robert W, Wagner Frank
University of Toronto Joint Centre for Bioethics, Toronto, Ontario, Canada.
Healthc Q. 2012;15(3):26-35. doi: 10.12927/hcq.2013.23040.
Drug supply shortages are common in health systems due to manufacturing and other delays. Frequently, shortages are successfully addressed through conservation and redistribution efforts, with limited impact on patient care. However, when Sandoz Canada Inc. announced in February 2012 that it was reducing production of a number of generic injectable drugs at its Quebec facility, the scope and magnitude of the drug supply shortage were unprecedented in Canada. The potential for an extreme scarcity of some drugs raised ethical concerns about patient care, including the need to limit access to some health services. In this article, the authors describe the development and implementation of an ethical framework to promote equitable access to drugs and healthcare services in the context of a drug supply shortage within and across health systems.
由于生产及其他延误,药品供应短缺在卫生系统中很常见。通常,通过节约和重新分配措施,短缺问题能得到成功解决,对患者护理的影响有限。然而,当山德士加拿大公司于2012年2月宣布将削减其魁北克工厂多种通用注射药物的生产时,药品供应短缺的范围和规模在加拿大是前所未有的。一些药物极度稀缺的可能性引发了对患者护理的伦理担忧,包括限制某些医疗服务可及性的必要性。在本文中,作者描述了一个伦理框架的制定和实施情况,该框架旨在药品供应短缺的情况下,在卫生系统内部及不同卫生系统之间促进药品和医疗服务的公平可及性。